Share on StockTwits
 

Pharmacyclics (NASDAQ: PCYC) was downgraded by TheStreet from a “buy” rating to a “hold” rating in a research note issued on Thursday, StocKRatingsNetwork.com reports.

The analysts wrote, “Pharmacyclics Incorporated (PCYC) has been downgraded by TheStreet Ratings from buy to hold. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company’s earnings per share.”

Several other analysts have also recently commented on the stock. Analysts at Wedbush set a $165.00 price target on shares of Pharmacyclics in a research note to investors on Wednesday, March 20th. They now have an “outperform” rating on the stock. Separately, analysts at Morgan Stanley initiated coverage on shares of Pharmacyclics in a research note to investors on Tuesday, March 19th. They set an “equal weight” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Pharmacyclics from $60.00 to $70.00 in a research note to investors on Tuesday, February 19th.

Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Pharmacyclics has an average rating of “Buy” and an average price target of $93.20.

Shares of Pharmacyclics (NASDAQ: PCYC) opened at 76.33 on Thursday. Pharmacyclics has a one year low of $24.50 and a one year high of $95.85. The stock’s 50-day moving average is currently $86.28. The company has a market cap of $5.384 billion and a P/E ratio of 64.58.

Pharmacyclics (NASDAQ: PCYC) last released its earnings data on Thursday, February 14th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.33. The company had revenue of $57.96 million for the quarter, compared to the consensus estimate of $45.74 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was down 25.6% on a year-over-year basis. Analysts expect that Pharmacyclics will post $-0.36 EPS for the current fiscal year.

Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

To view TheStreet’s full report, visit www.thestreetratings.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.